1.Significance of detection of the autoantibodies in patients with rheumatoid Arthritis
Jing GUO ; Jing HE ; Ru LI ; Tian LIU ; Xia LIU ; Yongfu WANG ; Zhanguo LI
Journal of Chinese Physician 2011;13(4):477-479,483
Objective To explore the sensitivity of antibodies against RF,APF,AKA,anti-CCP in rheumatoid arthritis (RA) and analyze the relationship between these autoantibodies in RA.MethodsFive hundreds of RA patients were studied.Immunoturbidmetry was used to measure the RF-IgM.The enzyme-linked immunosorbent assay (ELISA) was used to measure the HRF-IgG,HRF-IgA and anti-CCP.Indirect immunofluorescence was used to measure the APF and AKA.ResultsThe seropositive rates of RF-IgM,anti-CCP,APF,HRF-IgG,AKA and HRF-IgA were 78.0%,70.8%,51.8%,48.4%,45.0% and 20.0% respectively.RF-IgM could not be detected in 110 patients while the seropositive rates of anti-CCP,APF,AKA,HRF-IgG and HRF-IgA were 41.8%,27.3%,22.7%,15.5% and 1.8% respectively.Anti-CCP could not be detected in 146 patients while the seropositive rates of RF-IgM,HRF-IgG,APF,AKA and HRF-IgA were 56.8%,24.7%,16.4%,8.9% and 7.5% respectively.The combined sensitivities of RF-IgM anti-CCP and APF were higher than others.The seropositive rates were 88.6%.ConclusionsRF-IgM and anti-CCP are sensitive antibodies for diagnosis of RA.Combinations RF-IgM with anti-CCP can significantly improve the sensitivity of diagnosis of RA.
2.Surgical treatment of solid pseudopapillary tumors of the pancreas
Dongkui XU ; Yongfu SHAO ; Hongwei LIN ; Chengfeng WANG ; Yantoo TIAN ; Ping ZHAO
Chinese Journal of General Surgery 1997;0(04):-
Objective To study the characteristics of the solid pseudopapillary tumors of the pancreas (SPT) ,and to improve the diagosis and management of SPT. Methods Fourteen cases of solid pseudopapillary tumors of the pancreas admitted from Jan 1999 to Jul 2005 were analyzed retrospectively. Results There were 1 male and 13 females. Tumors were all single and mainly located in the head of the pancreas (9/14, 64. 3% ) , tumors in the other 5 cases were in the body and tail of the pancreas. The average diameter was 7.2 cm, with no specific symptom. On CT scan tumors were of low density, well-circumscribed with calcification, solid tumors were enhanced slightly on contrast medium, but cystic tumors were not enhanced . Simple resection was performed in 8 cases. Partial resection of the body of the pancreas and pancreaticojejunostomy was performed in 2 cases. One patient underwent distal pancreatectomy and splenectomy. Pancreaticoduodenectomy was performed in 3 cases. All the cases were followed up for an average of 20. 1 months with no recurrences. Conclusions Solid-pseudopapillary tumor of the pancreas is of low-grade malignancy. Surgical resection is effective. Surgical procedures adopted depend on the location and size of the tumor. Complete resection results in good prognosis.
3.Identification of Metabolized Polychlorinated Biphenyls in Fishery Products by Gas Chromatography-Tandem Mass Spectrometry
Yongfu SHI ; Youqiong CAI ; Huijuan YU ; Liangliang TIAN ; Xuanyun HUANG ; Dongmei HUANG
Chinese Journal of Analytical Chemistry 2014;(11):1640-1645
Gaschromatography-tandemmassspectrometrywasadoptedtoidentifythehydroxylatedmetabolites of polychlorinated biphenyls and analyze the target compounds in fishery products. After the silylation derivatizaiton at 60 ℃ for 40 min, the MS spectrum of derivatives was obtained by GC/MS/MS under fullscan mode, and the fragment ions with the highest relative abundance were identified as m/z 399, 399, 399, 399, 399, 448 and 469, respectively which were defined as the precursor ion for product ion scan. The MS/MS spectrum was obtained under multiple reaction mode ( MRM ) by GC/MS/MS. And the product ions corresponded with the precursor ions were m/z 364, 364, 364, 364, 364, 433 and 434, respectively. The target compounds can be identified accurately by GC/MS/MS. In the present study, we took seven hydroxylated polychlorinated biphenyls as target compounds including 3-OH-PCB101 , 4-OH-PCB106 , 4-OH-PCB112 , 4'-OH-PCB101 , 3-OH-PCB118 , 3-OH-PCB138 and 3-OH-PCB180 . According to the identification method stated as above, the MS and MS/MS spectra of seven compounds were obtained. The compounds can be qualified and quantified by the identification method. The limits of detection ranged from 0. 02 to 0. 14 μg/L, and the limits of quantification ranged from 0. 09 to 0. 48 μg/L. The method has been applied to identify the hydroxylated polychlorinated biphenyls in fishery products.
4.Survey on prevalence of dyslipidemia among children and adolescents aged 6-18 years old in Yinchuan
Wenqing DING ; Yongfu TIAN ; Fei SONG ; Leina JIA ; Ling ZHANG
Chinese Journal of Applied Clinical Pediatrics 2018;33(17):1336-1340
Objective To assess the prevalence of dyslipidemia among children and adolescents aged 6-18 years in Yinchuan.Methods A stratified,random cluster sampling was used to select a target samples (1 939 cases) of children from elementary schools,middle schools and high schools in different age groups,with medium economic status.The levels of serum total cholesterol (TC),high-density lipoprotein cholesterol (HDL-C),low-density lipoprotein cholesterol (LDL-C),and triglycerides (TG) were measured.Results The prevalence of total dyslipidemia was 15.5 % (300/1 939 cases).The prevalence of high TG,high TC,high LDL-C,low HDL-C,high non-HDL-C and hyperlipemia were 5.8% (113/1 939 cases),0.8% (18/1 939 cases),1.1% (21/1 939 cases),10.6% (205/1 939 cases),0.9% (18/1 939 cases) and 6.4% (124/1 939 cases),respectively.Boys were more likely to have dyslipidemia than girls (17.7% vs.13.3%) and a low HDL-C level (13.1% vs.8.2%),and the differences between 2 groups were statistically significant (x2 =7.178,P =0.007;x2 =12.337,P < 0.001).Individuals aged 16-18 years had the highest prevalence of total dyslipidemia [19.1% (89/466 cases)] than other age groups,and the difference was statistically significant(x2 =11.393,P < 0.01).Prevalence of dyslipidemia among the obese,the overweight and the normal weight individuals were 39.7% (69/174 cases),20.8% (60/289 cases) and 11.6% (171/1 469 cases),respectively.Moreover,prevalence of dyslipidemia increased significantly with gravity of obesity,and the difference was statistically significant(x2 =100.180,P < 0.01).Individuals with abdominal obesity had higher prevalence rates of dyslipidemia than that of the non-abdominal obese individuals [31.5% (92/292 cases) vs.12.6% (207/1 064 cases)],and the difference was statistically significant (x2 =67.578,P < 0.01).Approximately 39.7% (69/174 cases) and 31.5 % (92/292 cases) obese individuals and abdominal obesity were candidates for taking intervention measures including nutritional counseling,school-based lifestyle as well as community fitness programs.Conclusions Screening and prevention should be regarded for dyslipidemia among children and adolescents,especially for boys and teenagers in Yinchuan.
5.Clinical characteristics of patients with rheumatic diseases and abnormal liver function
Chanyuan WU ; Mucong LI ; Xinwang DUAN ; Hongbin LI ; Yanhong WANG ; Qin LI ; Hui LUO ; Jian XU ; Lijun WU ; Yongfu WANG ; Cheng ZHAO ; Yongfei FANG ; Shudian LIN ; Dong XU ; Xinping TIAN ; Mengtao LI ; Xiaofeng ZENG
Chinese Journal of Internal Medicine 2023;62(9):1102-1113
Objective:To investigate the clinical characteristics of patients with rheumatic diseases and abnormal liver function, as well as determine the proportion and severity of liver function abnormalities.Methods:Cross-sectional study. Data were collected from patients registered in the Chinese Rheumatism Date Center from 2011 to 2021. The rheumatic diseases analyzed in this study were rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren syndrome (SS), ankylosing spondylitis (AS), and gout. Patient data, including demographic characteristics [ such as age, sex, body mass index,(BMI), and smoking history], liver function test results [including alanine aminotransferase (ALT), aspartate aminotransferase, alkaline phosphatase(ALP), and total bilirubin], and use of anti-rheumatic immune drugs and liver-protective drugs, were collected and compared between groups with normal and abnormal liver functions. In addition, the proportions of abnormal liver function were compared between sex and age groups.Results:A total of 116 308 patients were included in this study, including 49 659 with RA, 17 597 with SLE, 9 039 with SS, 11 321 with AS, and 28 692 with gout. The lowest proportion of liver function abnormalities was observed in patients with RA[11.02% (5 470/49 659)], followed by those with SS[17.97% (1 624/9 039)] and AS [18.22% (2 063/11 321) ], whereas patients with SLE [21.14% (3 720/17 597) ] and gout [28.73% (8 242/28 692)] exhibited the highest proportion of these abnormalities. Elevated ALT, mostly classified as grade 1, was the most commonly noted liver function abnormality, whereas elevated ALP was the least common. Some patients who took liver-protective drugs had normal liver function, with the lowest percentage observed in patients with gout [7.45% (36/483) ] and ranging from 21.7% to 30.34% in patients with RA, SLE, SS, and AS. The proportion of liver function abnormalities was higher in males than in females for all disease types [RA: 13.8%(1 368/9 906) vs. 10.3%(4 102/39 753); SLE: 33.6% (479/1 424) vs. 20.0% (3 241/16 173); SS: 25.4%(111/437) vs. 17.6%(1 513/8 602); AS: 20.1%(1 629/8 119) vs. 13.6% (434/3 202); and gout: 29.3% (8 033/27 394) vs. 16.1% (209/1 298)]. In RA, SLE, and AS, the proportions of liver function abnormalities were similar across all age groups. In SS, the proportion of liver function abnormalities increased with age [<40 years: 14.9%(294/1 979); 40-59 years: 18.1%(858/4 741); ≥60 years: 20.4%(472/2 319)], whereas a reversal of this trend was observed in gout [<40 years: 34.9%(4 294/12 320); 40-59 years: 25.5%(2 905/11 398);≥60 years: 21.0%(1 042/4 971)].Conclusions:The proportions of combined liver function abnormalities in patients with rheumatologic diseases were high, and the utilization rates of liver-protective drugs were low. It is necessary to pay more attention to monitoring patients′ liver function, timely administer liver-protective drugs, and optimize liver-protective regimens during the treatment of rheumatic diseases.